Novoron Bioscience Raises $3M in Seed Financing from Two Bear Capital
Novoron Bioscience, a San Diego-based biotechnology company developing first-in-class therapies to reverse central nervous system (CNS) damage, announced today that they secured a $3 million Seed investment from Two Bear Capital (TBC).
Biotech company Novoron to open Missoula branch in pursuit of cure for spinal injuries
A San Diego-based biotech company this week announced its plans to expand into Missoula, where it looks to open an office and build a team in its pursuit of curing injuries to the central nervous system.
Novoron Bioscience Teams with Expesicor to Develop Neuroregenerative Compounds for Epilepsy and Alzheimer’s Disease
Novoron Bioscience announced a strategic partnership today with Expesicor to develop Novoron’s novel compounds to treat epilepsy and neurodegenerative disorders.
Developing Next Gen Multiple Sclerosis Therapies: Part 5
We are going to parse out myth vs. reality, explain how we address the innovation gap, and how we can improve the system to make the best possible drugs for the future.
Developing Next Gen Multiple Sclerosis Therapies: Part 4
In this article, we will discuss the different players involved in medical innovation, including their roles (and how those roles have evolved over time).
Developing Next Gen Multiple Sclerosis Therapies: Part 3
Now that we have set the stage with the drug development process, we can begin to examine possible ways to adapt the system and improve outcomes. We know that the rate of new therapies and cures has slowed, so how can we right the ship and accelerate innovation?
Developing Next Gen Multiple Sclerosis Therapies: Part 2
So how exactly does a drug come to the market?
Developing Next Gen Multiple Sclerosis Therapies: Part 1
For most people, medicine can be another language. It can be intimidating, even scary. However, modern medicine can also be miraculous and a tremendous source of hope.
The Johnson & Johnson Under 40 to Watch List: 6 Young Trailblazing Scientists
Johnson & Johnson recently identified six young scientists working toward the next great breakthroughs in healthcare. Novoron Bioscience's CEO & President, Dr. Travis Stiles, was named one of the six.
Dr. Stiles Named 2016 Catalyst by Biocom
Novoron's CEO & President, Dr. Travis Stiles, was recognized by Biocom: Life Science Association of California, in conjunction with the San Diego Venture Group, with a 2016 Catalyst Award.
Innovative Neuroscience Company Shows at RESI Challenge
Novoron Bioscience took home 3rd Prize in the 2016 Redefining Early Stage Investments (RESI) Innovation Challenge.
Novoron Recognized as Innovative San Diego Biotech
Our City San Diego named Novoron in the magazine’s list of 25 leading life science companies that could positively impact the San Diego economy in the coming years.
Xconomy Recognizes Novoron as San Diego Life Science Startup to Watch in 2016
Interview: Remyelination in MS with Novoron Bioscience
Brett Drummond interviews Dr. Travis Stiles on Remyelination in MS.
